Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
JIB
GLOBETECH PUBLISHING

Major European Research Project to Focus on Detection and Prevention of Rheumatoid Arthritis

By BiotechDaily International staff writers
Posted on 14 Aug 2013
The European Union has agreed to fund a multimillion euro research project aimed at detection and prevention of rheumatoid arthritis in individuals who do not yet have symptoms of the disease.

Funding for the first four years of the EuroTEAM (Towards Early diagnosis and biomarker validation in Arthritis Management) project will be more than 5.7 million euros. These funds will underwrite the research efforts of 13 academic partners from six European countries - the United Kingdom, the Netherlands, Sweden, Switzerland, Germany, and Austria, as well as three industry partners, from Germany, the Netherlands, and Iceland.

The biotech company ORGENTEC Diagnostika (Mainz, Germany), which will head up the search for biomarkers in the blood, will be a major player on EuroTEAM. ORGENTEC is a global leader in development, production, and marketing of test systems for laboratory diagnostics. The company offers numerous highly specific ELISA tests, immunoblots, and kits for immunofluorescence assays. Its point of care test "rheumachec" was the first rapid test for diagnosing rheumatoid arthritis.

In the case of a chronic inflammatory disease such as rheumatoid arthritis, the goal is prevention. Development of preventive strategies and therapies requires (1) identification of biomarkers that can be used to predict an individual's risk of developing the disease, and (2) identification and characterization of modifiable disease mechanisms that can be manipulated in the early phases of disease.

The key objective of the TEAM consortium is to specifically identify diagnostic biomarkers and disease mechanisms operating during the transition from health to rheumatoid arthritis. The plan is to achieve this by developing a collaborative, integrated program of work that will link academic researchers with key SMEs (small and medium sized enterprises) involved in biomarker development to produce a personalized predictive biomarker profile for patients destined to develop rheumatoid arthritis. Ultimately, the project will directly involve other medical specialists and patients.

Related Links:
ORGENTEC Diagnostika



comments powered by Disqus

Channels

Drug Discovery

view channel
Image: The European Commission has approved the use of Avastin combined with chemotherapy as a treatment for women with recurrent ovarian cancer (Photo courtesy of Genentech).

Drug for Treatment of Platinum Resistant Recurrent Ovarian Cancer Approved for Use in Europe

For the first time in more than 15 years the European Commission (EC) has approved a new therapeutic option for the most difficult to treat form of ovarian cancer. Ovarian cancer causes more deaths... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Lab Technologies

view channel
Image: The DrySyn MULTI converts any standard hotplate stirrer into a high performance reaction block (Photo courtesy of Asynt).

New Reaction Vessel Heating System Is Cleaner and Safer

Biotech and other life science researchers can create a safer, cleaner, and more efficient working environment in their laboratories by switching from oil bath-based heating of reaction vessels to a new... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.